Protox appoints new directors

Protox Therapeutics (TSX:PRX) is appointing William Rohn and Amit Sobti to the board. Mr. Rohn has over 30 years of experience as a senior executive in the pharmaceutical and biotech industry. He retired in January, 2005 as COO of Biogen-Idec, playing an instrumental role in the $6.8 billion merger of IDEC Pharmaceuticals and Biogen. Mr. [...]

Prescription for growth

We, at biotuesdays.com, attended Dundee Capital Markets’ second emerging growth conference last week, where over 20 technology, life sciences and industrial growth companies presented. Dundee specializes in early-stage growth, and to say that the one-day showcase was jammed full of investment ideas is a bit of understatement. Here’s a sampling of what we took away [...]

Protox gets credibility boost from Warburg Pincus

An equity injection of up to $35 million from private equity giant Warburg Pincus represents a huge vote of confidence in Protox Therapeutics (TSX:PRX) and its lead PRX302 drug for enlarged prostate or benign prostatic hyperplasia (BPH), with the drug potentially able to target two other diseases: prostate cancer and prostatitis. “We went through an [...]

Protox has positive six-month Phase 2b BPH results

Protox Therapeutics (TSX:PRX) has released positive six-month data from its Phase 2b TRIUMP study of its PRX302 drug in patients with moderate-to-severe benign prostatic hyperplasia. The study met its primary endpoint with a statistically significant improvement in International Prostate Symptom Score at day-90 for patients treated with PRX302 versus placebo and requires additional patient assessments [...]